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Abstract
Introduction: Honokiol, a small-molecule polyphenol isolated from magnolia species, is widely known for its
therapeutic potential as an antiinflammatory, antithrombosis, and antioxidant agent, and more recently, for its
protective function in the pathogenesis of carcinogenesis. In the present study, we sought to examine the
effectiveness of honokiol in inhibiting migration and invasion of breast cancer cells and to elucidate the underlying
molecular mechanisms.
Methods: Clonogenicity and three-dimensional colony-formation assays were used to examine breast cancer cell
growth with honokiol treatment. The effect of honokiol on invasion and migration of breast cancer cells was
evaluated by using Matrigel invasion, scratch-migration, spheroid-migration, and electric cell-substrate impedance
sensing (ECIS)-based migration assays. Western blot and immunofluorescence analysis were used to examine
activation of the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) axis. Isogenic LKB1-knockdown breast
cancer cell line pairs were developed. Functional importance of AMPK activation and LKB1 overexpression in the
biologic effects of honokiol was examined by using AMPK-null and AMPK-wild type (WT) immortalized mouse
embryonic fibroblasts (MEFs) and isogenic LKB1-knockdown cell line pairs. Finally, mouse xenografts,
immunohistochemical and Western blot analysis of tumors were used.
Results: Analysis of the underlying molecular mechanisms revealed that honokiol treatment increases AMP-
activated protein kinase (AMPK) phosphorylation and activity, as evidenced by increased phosphorylation of the
downstream target of AMPK, acetyl-coenzyme A carboxylase (ACC) and inhibition of phosphorylation of
p70S6kinase (pS6K) and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1). By using AMPK-null and
AMPK-WT (MEFs), we found that AMPK is required for honokiol-mediated modulation of pACC-pS6K. Intriguingly,
we discovered that honokiol treatment increased the expression and cytoplasmic translocation of tumor-suppressor
LKB1 in breast cancer cells. LKB1 knockdown inhibited honokiol-mediated activation of AMPK and, more important,
inhibition of migration and invasion of breast cancer cells. Furthermore, honokiol treatment resulted in inhibition of
breast tumorigenesis in vivo. Analysis of tumors showed significant increases in the levels of cytoplasmic LKB1 and
phospho-AMPK in honokiol-treated tumors.
Conclusions: Taken together, these data provide the first in vitro and in vivo evidence of the integral role of the
LKB1-AMPK axis in honokiol-mediated inhibition of the invasion and migration of breast cancer cells. In conclusion,
honokiol treatment could potentially be a rational therapeutic strategy for breast carcinoma.
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Introduction
Breast cancer is one of the most common cancers and the
second leading cause of cancer-related mortality in
women. About 226,870 new cases of invasive breast cancer
and about 63,300 new cases of carcinoma in situ will be
diagnosed in 2012, according to the latest estimates for
breast cancer in the United States by American Cancer
Society. Despite major advances in screening programs
and development of various targeted therapeutic
approaches, mortality related to breast cancer still remains
at a staggering high level, with approximately 1 in 35
women dying of breast cancer. Available therapies, includ-
ing radiation, endocrine, and conventional chemotherapy,
are often limited by high toxicity, lower efficacy, therapeu-
tic resistance, and therapy-related morbidity. Therefore,
more-effective therapeutic strategies are clearly needed to
combat breast cancer and to reduce morbidity and
mortality.
The importance of active constitutive agents in natural
products has become increasingly apparent, owing to their
potential cancer preventive as well as therapeutic proper-
ties [1,2]. In traditional Asian medicine, root and stem
bark of Magnolia species have been used for centuries to
treat anxiety, nervous disorders, fever, gastrointestinal
symptoms, and stroke [3]. Therapeutic benefits of Magno-
lia species have been attributed to honokiol, a natural phe-
nolic compound isolated from an extract of seed cones
from Magnolia grandiflora [3,4]. Honokiol has shown
antithrombocytic, antibacterial, antiinflammatory, antioxi-
dant, and anxiolytic effects, and it may prove beneficial
against hepatotoxicity, neurotoxicity, thrombosis, and
angiopathy [3]. Two pioneering studies showing the
remarkable inhibitory effects of honokiol on mouse skin-
tumor promotion and demonstrating efficacy of honokiol
against established tumors in mice [5,6] ascertained the
anticancer potential of honokiol. Subsequent studies
showed the anticancer activities of honokiol in many can-
cer cell lines and tumor models [7-11].
Honokiol has been found to alter many cellular pro-
cesses and to modulate molecular targets that are known
to affect apoptosis, growth, and survival of tumor cells. A
review of previous studies suggests that the mechanism
by which honokiol causes growth arrest and cell death
may be cell-line/tumor-type specific and involve many
signaling pathways. For instance, Bax upregulation has
been observed in some but not in other cellular systems
[7,12]. Honokiol decreases phosphorylation of ERK, Akt,
and c-Src to induce apoptosis effectively in SVR angiosar-
coma cells [3], inhibits the ERK signaling pathway to
exert antiangiogenesis activity [13], but activates ERK in
cortical neurons to induce neurite outgrowth [14,15]. In
chronic lymphocytic leukemia (CLL), honokiol causes
apoptosis through activation of caspase 8, followed by
caspase 9 and 3 activation [7]. Honokiol-mediated
increased cleavage of Mcl-1 and downregulation of XIAP
as well as BAD upregulation is observed in multiple mye-
loma, whereas Bid, p-Bad, Bak, Bax, Bcl-2, and Bcl-xL
remain unchanged [12]. Honokiol also inhibits the NF-
B signaling pathway, thus affecting expression of many
downstream genes in endothelial cells, human mono-
cytes, lymphoma, embryonic kidney cells, promyelocytic
leukemia, multiple myeloma, breast cancer, cervical can-
cer, and head and neck cancer [16-19]. Thus, honokiol
elicits several cellular responses and modulates multiple
facets of signal transduction.
In the present study, we specifically investigated the
effect of honokiol on the malignant properties of breast
cancer cells, including migration and invasion, and also
examined the underlying molecular mechanisms. Intri-
guingly, we discovered that honokiol increases the
expression of tumor-suppressor LKB1 to modulate the
signaling pathway involving the AMPK-pS6K axis. We
directly tested the requirement of AMPK and LKB1 in
honokiol-mediated inhibition of malignant properties of
breast cancer cells. Our results showed that LKB1 and
AMPK are integral molecules required for honokiol-
mediated modulation of 4EBP1-pS6K and inhibition of
migration and invasion of breast cancer cells.
Materials and methods
Cell culture and reagents
The human breast cancer cell lines, MCF7 and MDA-
MB-231, were obtained from the American Type Culture
Collection and maintained in DMEM supplemented with
10% fetal bovine serum (FBS) (Gemini Bioproducts,
Woodland, CA, USA) and 2 μM L-glutamine (Invitrogen,
Carlsbad, CA, USA). Cell-line authentication was done
by analysis of known genetic markers or response (for
example, expression of estrogen receptor and p53 and
estrogen responsiveness) [20]. AMPK-null and AMPK-
WT immortalized MEFs were kindly provided by Dr.
Keith R. Laderoute (SRI International, Menlo Park, CA,
USA) [21]. Honokiol is a natural product extracted from
seed cone of Magnolia grandiflora, as previously
described [6]. Antibodies for p-AMPK (phospho-AMPK),
AMPK, ACC, p-ACC (phospho-ACC), pS6K, p-pS6K
(phospho-S6K), 4EBP1, p-4EBP1 (phospho-4EBP1),
p-Akt (phospho-Akt), Akt, and LKB1 (3047) were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA).
LKB1 stable knockdown using lentiviral short-hairpin RNA
Five pre-made lentiviral LKB1 short-hairpin RNA
(shRNA) constructs and a negative control construct
created in the same vector system (pLKO.1) were pur-
chased from Open Biosystems (Huntsville, AL, USA).
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Paired LKB1 stable knockdown cells (MCF7 and MDA-
MB-231) were generated by following our previously
published protocol [22].
Cell-viability assay
Cell-viability assay was performed by estimating the
reduction of XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-
phenyl)-2H-tetrazolium-5-carboxyanilide), by using a
commercially available kit (Roche) [23]. Breast cancer
cells were treated with honokiol as indicated.
Clonogenicity assay
For colony-formation assay [24], MCF7 and MDA-MB-
231 cells were treated with honokiol as indicated for
10 days; colonies containing > 50 normal-appearing cells
were counted.
Anchorage-independent soft-agar growth assay
Anchorage-independent growth of MCF7 and MDA-
MB-231 cells in the presence of honokiol treatment was
determined by colony formation on soft agar [25]. Colo-
nies were counted in five randomly selected fields at
×10 magnification by using Olympus IX50 inverted
microscope.
Scratch-migration assay
Migration assay was performed according to our pub-
lished protocol [26]. Cells were treated with honokiol as
indicated. Plates were photographed after 24 and
48 hours at the identical location of the initial image.
Electric cell-substrate impedance sensing (ECIS) wound-
healing assay
Wound-healing assay was performed by using the ECIS
(Applied BioPhysics, Troy, NY, USA) technology and
following our previously established protocol [27].
Spheroid migration assay
MDA-MB-231 and MCF7 cells (1.5 × 104) were seeded in
0.5% agar-coated plates and cultured on an orbital shaker
(100 rpm) for 48 hours in a humidified atmosphere con-
taining 5% CO2 at 37°C. Intact tumor spheroids were
selected and transferred to six-well plates. The spheroids
were treated with honokiol, as indicated. After 48 hours
of incubation, spheroids were fixed with 10% buffered
formalin in PBS and stained with crystal violet. The
migration of cells from spheroids was observed under a
light microscope.
Invasion assay
For an in vitro model system of metastasis, Matrigel inva-
sion assay [28] was performed by using a Matrigel invasion
chamber from BD Biocoat Cellware (San Jose, CA, USA).
The slides were coded to prevent counting bias, and the
number of invaded cells on representative sections of each
membrane were counted under light microscope. The
number of invaded cells for each experimental sample
represents the average of triplicate wells.
Western blotting
Whole cell lysate [23] was prepared by scraping MCF7
and MDA-MB-231 cells in 250 μl of ice-cold modified
RIPA buffer. An equal amount of protein was resolved
on sodium dodecylsulfate polyacrylamide gel, transferred
to nitrocellulose membrane, and Western blot analysis
was performed. Immunodetection was performed by
using enhanced chemiluminescence (ECL system; Amer-
sham Pharmacia Biotech, Arlington Heights, IL, USA)
according to manufacturer’s instructions.
Immunoprecipitation assay
Immunoprecipitation of LKB1 was performed by follow-
ing the previously published protocol [23] by using anti-
LKB1 antibody followed by immunoblotting with anti-
STRAD antibody.
Immunofluorescence and confocal imaging
Breast cancer cells (5 × 105 cells/well) were plated in
four-well chamber slides (Nunc, Rochester, NY, USA)
followed by treatment with honokiol and subjected to
immunofluorescence analysis as described [22]. Fixed
and immunofluorescently stained cells were imaged by
using a Zeiss LSM510 Meta (Zeiss) laser scanning con-
focal system configured to a Zeiss Axioplan 2 upright
microscope with a 63XO (NA 1.4) plan-apochromat
objective. All experiments were performed multiple
times by using independent biologic replicates.
Breast tumorigenesis assay
MDA-MB-231 (5 × 106) cells in 0.1 ml of HBSS were
injected subcutaneously into the right gluteal region of
4- to 6-week-old female athymic nude mice. Two weeks
after initial implantation, the animals were placed into
two experimental groups. Mice were treated with intra-
peritoneal injections of (a) control (saline and Intralipi-
dor (b) honokiol, at 3 mg/mouse/day in 20% Intralipid
(Baxter Healthcare, Deerfield, IL, USA), 3 times per
week for the duration of the experiment. Tumors were
measured by using vernier calipers, with tumor volume
calculated by using the formula (V = a/2 × b2), where V
is the tumor volume in cubic millimeters, and a and b
are the largest and smallest diameters in millimeters,
respectively. All animals were killed after 4 weeks of
treatment. Tumors were collected; weighed, fixed in
10% neutral-buffered formalin; and subjected to further
analysis with immunohistochemistry.
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Immunohistochemical analysis
We used tumor sections to determine the effect of hono-
kiol on expression of p-AMPK, LKB1, and Ki-67 by immu-
nohistochemistry. Immunohistochemistry was performed
essentially as described by us previously for other proteins
[25,26]. At least four nonoverlapping representative
images from each tumor section from five mice of each
group were captured by using ImagePro software for
quantitation of p-AMPK, LKB1, and Ki-67 expression.
Total cell lysates were prepared from tumor samples and
subjected to immunoblot analysis. All animal studies were
conducted in accordance with the guidelines of University
ACUC.
Statistical analysis
All experiments were performed thrice in triplicates. Sta-
tistical analysis was performed by using Microsoft Excel
software. Significant differences were analyzed by using
the Student t test and two-tailed distribution. Data were
considered to be statistically significant if P < 0.05. Data
were expressed as mean ± SEM between triplicate experi-
ments performed thrice.
Results
Honokiol treatment inhibits clonogenicity, migration, and
invasion of breast cancer cells
Growth-inhibition and apoptosis-induction properties of
honokiol have been reported in several cancer cell lines
[3,9-12,18]. In the current study, two breast cancer cell
lines, MCF7 and MDA-MB-231, were treated with various
concentrations ranging from 1 μM to 25 μM honokiol and
subjected to clonogenicity (Figure 1a) and anchorage-inde-
pendent growth assay (Figure 1b). Dose-dependent and
statistically significant inhibition of clonogenicity and soft-
agar colony formation was observed in the presence of
honokiol. Treatment with 5 μM honokiol resulted in
~50% to 60% inhibition in clonogenicity and soft-agar col-
ony formation, whereas higher concentrations (10 and 25
μM) were more inhibitory (Figure 1a, b). We further
examined the effect of honokiol on the growth of
HCC1806 breast cancer cells, which harbor an LKB1
homozygous mutation, by using clonogenicity and soft-
agar colony formation assay. Our studies show that hono-
kiol does not inhibit the growth of HCC-1806 cells (Addi-
tional file 1). These results indicate that LKB1 might be an
integral molecule for honokiol-mediated growth
inhibition.
Cancer progression is a multistep process that involves
invasion of basement membrane by tumor cells and
migration to points far from a given primary tumor mass,
leading to metastasis [29]. We examined the effect of
honokiol on breast cancer cell migration and invasion by
using scratch migration, electric-cell-substrate impedance
sensing (ECIS)-based migration, spheroid migration, and
Matrigel invasion assays. Honokiol treatment resulted in
inhibition of migration of breast cancer cells (Figure 2a)
in comparison with untreated cells. For quantitative
determination of alteration in the migration potential of
breast cancer cells on treatment with honokiol, we per-
formed a quantitative real-time impedance assay by using
an ECIS-based technique. As expected, confluent cells
showed high resistance values. Confluent cells were sub-
jected to a high-voltage pulse that resulted in decrease in
resistance, indicating death and detachment of cells pre-
sent on the small active electrode. Cells were left
untreated or treated with honokiol, and changes in resis-
tance were recorded for 24 hours. Control untreated cells
showed an increase in resistance, showing increased
migration of cells surrounding the small active electrode
that were not submitted to the elevated voltage pulse to
reach the resistance values of the nonwounded cells at
the start of the experiment. Honokiol-treated cells
showed a decrease in resistance, indicating decreased
migration. Notably, honokiol-treated cells never reached
the values of nonwounded cells, showing significant inhi-
bition of migration potential (Additional file 2). We
examined the effect of honokiol treatment on the migra-
tory capacity of MCF7 and MDA-MB-231 cells spher-
oids. Significant migration of MCF7 and MDA-MB-231
cells from the spheroids was seen under untreated condi-
tions. Honokiol treatment resulted in inhibition of migra-
tion of cells from spheroids (Figure 2b). Next, we
performed Matrigel invasion assay to examine the effect
of honokiol on the invasion potential of breast carcinoma
cells. As evident from Figure 2c, honokiol treatment
decreased invasion of breast cancer cells through Matri-
gel in comparison with untreated cells. Activation of
FAK has been shown to regulate cancer cell migration
and invasion through distinct pathways by promoting the
dynamic regulation of focal adhesion and peripheral actin
structures [30-32] and matrix metalloproteinases
(MMPs)-mediated matrix degradation [33]. We exam-
ined whether honokiol treatment affects FAK activation
to inhibit migration and invasion of breast cancer cells.
Honokiol treatment inhibited FAK phosphorylation in
breast cancer cells, indicating the involvement of FAK
activation in honokiol-mediated inhibition of migration
and invasion potential of breast cancer cells (Figure 2d).
Collectively, these results show that honokiol treatment
can effectively inhibit clonogenicity, anchorage-indepen-
dent colony formation, migration, and invasion of breast
carcinoma cells.
Honokiol-induced AMPK activation plays an integral role
in honokiol-mediated inhibition of mTOR activity and
migration potential of cells
Honokiol modulates multiple pathways (nuclear factor
(NF)-B, ERK, Akt, and JNK) in a cellular process and
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target-tissue-dependent manner [7,9-11,19]. AMP-acti-
vated protein kinase (AMPK) is a serine/threonine pro-
tein kinase that acts as a master sensor of cellular energy
balance in mammalian cells by regulating glucose and
lipid metabolism [34]. Recent studies have implicated
AMPK as an important factor in cancer cell growth and
migration [35,36]. Thus, we sought to determine the
effect of honokiol on AMPK phosphorylation and activa-
tion. Honokiol treatment stimulated phosphorylation of
AMPK at Thr-172 in MCF7 and MDA-MB-231 cells.
Honokiol had no effect on total AMPK protein expres-
sion levels (Figure 3a). AMPK phosphorylation at
Figure 1 Honokiol inhibits clonogenicity and anchorage-independent growth of breast cancer cells. (a) MCF7 and MDA-MB-231 cells
were treated with various concentrations of honokiol (HNK) (as indicated) and subjected to clonogenicity assay. U, untreated cells. Colonies
containing > 50 normal-appearing cells were counted. *P < 0.005, compared with untreated controls. (b) Breast cancer cells were subjected to
soft-agar colony-formation assay in the presence of various concentrations of honokiol for 3 weeks. Results are expressed as average number of
colonies counted (in six microfields). *P < 0.001, compared with untreated controls.
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Figure 2 Honokiol inhibits migration and invasion of breast cancer cells. (a) MCF7 and MDA-MB-231 cells were subjected to scratch-
migration assay. Culture media were replaced with media containing honokiol (2.5 μM) or untreated media (U). The 100-ng/ml epidermal
growth factor (EGF) treatment was used as positive control. The plates were photographed at the identical location of the initial image (0 hours)
at 24 hours. The results shown are representative of three independent experiments performed in triplicate. The histogram shows the fold
change in migration. *P < 0.01, compared with untreated controls. (b) MCF7 and MDA-MB-231 cells were subjected to spheroid-migration assay.
Culture media were replaced with media containing honokiol (2.5 μM) or untreated media (U). The spheroids were photographed 48 hours after
treatment. The results shown are representative of three independent experiments performed in triplicate. The histograms show percentage
migration. *P < 0.01, compared with untreated controls. (c) MCF7 and MDA-MB-231 cells were cultured in Matrigel invasion chambers followed
by treatment with honokiol (HNK, 1.0, 2.5 μM) for 24 hours, as indicated. U, untreated controls. The number of cells that invaded through the
Matrigel was counted in five different regions. The slides were blinded to remove counting bias. The histograms show the mean of three
independent experiments performed in triplicate. *P < 0.005, compared with untreated controls. (d) Breast cancer cells (MDA-MB-231) were
treated with honokiol (HNK, 2.5 μM) for indicated time intervals. U, untreated cells. Total protein was isolated, and equal amounts of proteins
were resolved with SDS-PAGE and subjected to immunoblot analysis by using specific antibodies for phosphorylated FAK. The membranes were
reblotted by using total FAK antibodies as controls. The blots are representative of multiple independent experiments.
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Thr-172 has been widely associated with its activation
[37]. Once activated, AMPK directly phosphorylates and
inactivates a number of ATP-consuming metabolic
enzymes including acetyl-coenzyme A carboxylase (ACC)
[38]. We examined the phosphorylation of ACC to evalu-
ate AMPK activity with honokiol treatment. Increased
phosphorylation of ACC in MCF7 and MDA-MB-231
cells was observed in response to honokiol treatment as
compared with untreated cells, whereas total ACC pro-
tein levels remain unchanged (Figure 3a). Activation of
AMPK leads to suppression of mammalian target of
rapamycin (mTOR) signaling, and the molecular
mechanisms involve phosphorylation of tuberous sclero-
sis complex protein TSC2 at Thr-1227 and Ser-1345 that
increases the activity of the TSC1-TSC2 complex to inhi-
bit mTOR [37,39]. Two very well characterized and
widely studied downstream effectors of mTOR are the
p70 kDa ribosomal protein S6 kinase 1 (p70S6K1 or
pS6K) and the eukaryotic translation initiation factor 4E
(elF4E)-binding protein (4EBP1) [40]. Phosphorylation of
pS6K and 4EBP1 has been widely used to assess changes
in mTOR activity in response to various growth-factor
pathways. We next examined the effect of honokiol on
mTOR activity in breast cancer cells. Honokiol decreased
phosphorylation of pS6K and 4EBP1 in both MCF7 and
MDA-MB-231 cells while not affecting the total protein
levels of pS6K and 4EBP1 (Figure 3b). Recent studies
have shown that pS6K regulates the actin cytoskeleton by
acting as an actin filament cross-linking protein and as a
Rho family GTPase-activating protein [41]. It has been
shown that reorganization of the actin cytoskeleton is cri-
tical for cell migration, as motile cancer cells must
assemble and disassemble the actin filaments at their
leading edges [42]. Depletion or inhibition of the activity
of pS6K results in inhibition of actin cytoskeleton reorga-
nization and inhibition of migration [41]. Owing to the
integral role of pS6K in cancer cell migration, it is possi-
ble that honokiol-mediated inhibition of migration is
mediated through pS6K inhibition.
mTOR, a key regulator of cell growth and proliferation,
exists in two structurally and functionally distinct multi-
protein complexes, mTORC1 and mTORC2. mTORC1 is
known to activate protein synthesis and cell growth
through regulating pS6K and 4E-BP1 activity, whereas
mTORC2 phosphorylates Akt on Ser-473, activating cell
growth, proliferation, and survival [43,44]. We found that
honokiol increases AMPK activation and inhibits
mTORC1 function, as evidenced by inhibition of pS6K
and 4E-BP1 phosphorylation.
We next determined whether honokiol treatment mod-
ulates mTORC2 function. mTORC2 phosphorylates Akt
on Ser-473. Therefore, to determine whether mTORC2 is
also inhibited by honokiol under similar conditions,
breast cancer cells were treated with honokiol, and the
phosphorylation of Akt was determined. Honokiol did
not alter Akt phosphorylation on Ser-473 in breast can-
cer cells (Additional file 3). These results provide evi-
dence that honokiol only inhibits mTORC1 in breast
cancer cells. Contrasting findings have been reported
previously, showing reduction in Akt phosphorylation in
response to honokiol treatment. Of note, MDA-MB-231
cells were treated with much higher concentrations of
honokiol (60, 80, and 100 μM) in this study [45]. Hence,
the observed decrease in Akt phosphorylation may
be due to the treatment with higher concentrations of
honokiol. Honokiol inhibits breast cancer growth in a
concentration-dependent manner, with higher concentra-
tions much more inhibitory than lower concentrations
(Figure 1).
Although our findings clearly showed the involvement
of AMPK activation in the honokiol signaling network,
we raised the question whether honokiol-induced inhibi-
tion of mTOR and cell migration requires AMPK pro-
tein. We used MEFs derived from AMPK-WT (WT)
and AMPK knockout (AMPK-null) mice to test the
potential requirement of this protein in honokiol-
mediated inhibition of migration. Immunoblotting con-
firmed the absence of the AMPK protein in AMPK-null
MEFs (Figure 4a). In agreement with the absence of
AMPK protein, the AMPK-null MEFs did not show any
phosphorylation of ACC, even in the presence of hono-
kiol. AMPK-WT MEFs, conversely, exhibited honokiol-
stimulated phosphorylation of ACC, indicating activa-
tion of AMPK (Figure 4b). Exposure of MEFs derived
from AMPK-WT mice to honokiol resulted in inhibition
of phosphorylation of pS6K, whereas the MEFs derived
from the AMPK-null mice were significantly resistant to
the honokiol-mediated inhibition of pS6K phosphoryla-
tion (Figure 4d).
We next asked whether AMPK is directly involved in
honokiol-mediated inhibition of migration. AMPK-WT
MEFs exhibited inhibition of migration in response to
honokiol treatment in scratch migration as well as
ECIS-based migration assay. Interestingly, honokiol
treatment could not inhibit migration of AMPK-null
MEFs (Figure 4c; Additional file 4). AMPK knockdown
also inhibited the antiproliferative effect of honokiol
(Figure 4e). These results showed that AMPK is an inte-
gral molecule in mediating the negative effects of hono-
kiol on the mTOR axis and migration potential of cells.
Inhibition of LKB1 abrogates honokiol-mediated
modulation of AMPK and inhibition of migration and
invasion of breast cancer cells
The tumor suppressor LKB1 (also known as Stk11) is an
evolutionarily conserved serine/threonine protein kinase
that has a broad range of cellular functions, including
tumor suppression, cell polarity, cell-cycle regulation,
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Figure 3 Honokiol activates AMPK and inhibits pS6K and 4EBP1 phosphorylation in breast cancer cells. (a) MCF7 and MDA-MB-231 cells
were treated with honokiol (HNK, 2.5 μM) for indicated time intervals. U, untreated cells. Total protein was isolated, and equal amounts of
proteins were resolved with SDS-PAGE and subjected to immunoblot analysis by using specific antibodies for phosphorylated AMPK (pAMPK-Thr
172) and phosphorylated ACC (pACC). The membranes were reblotted by using total AMPK and ACC antibodies as controls. The blots are
representative of multiple independent experiments. The histogram is the mean of densitometric analysis showing relative density units (RDUs)
of the Western blot signal for pAMPK and pACC normalized to total AMPK or ACC in three separate experiments. *P < 0.005, compared with
untreated controls. (b) Breast cancer cells were treated with honokiol as in (a) and subjected to immunoblot analysis by using specific
antibodies for phosphorylated pS6K (p-pS6K) and phosphorylated 4EBP1 (p-4EBP1). The membranes were reblotted by using total pS6K and p-
4EBP1 antibodies as controls. The blots are representative of multiple independent experiments. The histogram is the mean of densitometric
analysis showing relative density units (RDUs) of the Western blot signal for p-pS6K and p-4EBP1 normalized to total pS6K or 4EBP1 in three
separate experiments. *P < 0.001, compared with untreated controls.
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Figure 4 AMPK knockdown abrogates honokiol-mediated increased phosphorylation of ACC, inhibition of phosphorylation of S6K,
and inhibition of migration. (a) Immunoblotting for AMPK protein by using lysates from untreated MEFs derived from AMPK-WT (WT) and
AMPK-knockout mice (AMPK-null). The blot was stripped and reprobed with anti-actin antibody. (b) WT and AMPK-null MEFs were treated with
honokiol (HNK, 2.5 μM) for indicated time intervals. U, untreated cell. Total protein was isolated, and equal amounts of proteins were resolved
with SDS-PAGE and subjected to immunoblot analysis by using specific antibodies for phosphorylated ACC (p-ACC). Anti-actin antibody was
used as control. (c) WT and AMPK-null MEFs were subjected to scratch-migration assay in the presence (HNK, 2.5 μM) or absence (U) of
honokiol. The plates were photographed at the identical location of the initial image (0 hours) at 24 hours. The histogram shows the fold
change in migration. *P < 0.001, compared with untreated controls. All the experiments were performed thrice in triplicate. (d) WT and AMPK-
null MEFs were treated with honokiol (HNK, 2.5 μM) for indicated time intervals. U, untreated cell. Total protein was isolated, and equal amounts
of proteins were resolved with SDS-PAGE and subjected to immunoblot analysis by using specific antibodies for phosphorylated pS6K (p-pS6K).
The membranes were reblotted by using total pS6K and actin antibody as control. (e) WT and AMPK-null MEFs were subjected to XTT assay in
the presence (HNK) or absence (U) of honokiol, as indicated. The results shown are representative of three independent experiments performed
in triplicate. *P < 0.001, compared with untreated controls.
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and promotion of apoptosis [46,47]. LKB1 has recently
been identified as a critical upstream kinase for AMPK,
regulating its activity. Intriguingly, we found that hono-
kiol increases expression of tumor suppressor LKB1 in
MCF7 and MDA-MB-231 cells, with a significant
increase at 1 hour of treatment with maximal expression
at 24 hours in MCF7 cells and at 4 hours in MDA-MB-
231 cells (Figure 5a). Variable expression of LKB1 in
MDA-MB-231 breast cancer cells has been reported
[48,49]. We recently procured MDA-MB-231 cells from
various established breast cancer research laboratories
and analyzed the expression and functional status of
LKB1. Our data unequivocally showed the presence of
functional LKB1 in MDA-MB-231 cells [22]. Human
LKB1 is both nuclear and cytoplasmic, but a mutant of
LKB1 lacking the nuclear localization signal still retains
the ability to suppress cell growth, suggesting that the
cytosolic pool of LKB1 plays an important role in med-
iating its tumor-suppressor properties [50,51]. STRAD
(Ste20-related adaptor) protein has been shown to form
a complex in which STRAD activates LKB1, resulting in
cytoplasmic translocation of LKB1 [47]. We investigated
the effect of honokiol on the formation of the LKB1-
STRAD complex in breast cancer cells. To address this
question, breast cancer cells were treated with honokiol
followed by immunoprecipitation with LKB1 antibodies.
Immunoprecipitated protein complexes were analyzed
for the presence of STRAD by using Western blot ana-
lysis. Higher levels of STRAD immunoprecipitated with
LKB1 in the presence of honokiol indicated increased
formation of the LKB1-STRAD complex (Figure 5b).
Immunostaining of honokiol-treated MCF7 and MDA-
MB-231 cells revealed that honokiol treatment increases
cytoplasmic accumulation of LKB1. LKB1 was localized
predominantly in the nucleus in untreated breast cancer
cells, although cytoplasmic LKB1 expression was also
detected (Figure 5c). Control experiments with second-
ary antibody (results not shown) gave an extremely faint
background staining that was distributed uniformly
throughout the cells, irrespective of the treatment. Stu-
dies on the subcellular localization of LKB1 have indi-
cated a wide variety of localization patterns. Mouse
LKB1 was found to be predominantly nuclear, whereas
Caenorhabditis elegans PAR-4 and Xenopus XEEK1
were detected exclusively in the cytoplasm [52-54].
Human LKB1 has been detected to be both nuclear and
cytoplasmic in several cell types [55,56]. Although LKB1
expression is exclusively cytoplasmic in lung and pan-
creatic cancer [57,58], gastrointestinal hamartomatous
polyps from Peutz-Jeghers syndrome patients, head and
neck squamous cell carcinoma, invasive lobular breast
carcinoma, and solid papillary ductal carcinoma in situ
breast cancer show both cytoplasmic and nuclear LKB1
expression [59-61]. Studies in adult rat primary
cardiomyocytes and C2C12 myoblasts showed that
LKB1 was located predominantly in nucleus and under-
goes cytoplasmic localization in various stimulations
[62-64]. In vitro studies suggest that nuclear LKB1 regu-
lates cell-cycle progression and acts as a transcription
factor [65,66], whereas cytoplasmic LKB1 participates in
controlling energy metabolism and cell polarity [67]. It
is not completely understood how subcellular localiza-
tion of LKB1 affects its tumor-suppressor function and
activation of other signaling pathways in vivo.
We raised the question whether LKB1 plays an impor-
tant regulatory role in honokiol- mediated modulation of
AMPK and inhibition of migration and invasion of breast
cancer cells. To address these questions, we used
LKB1shRNA lentivirus and puromycin to select for stable
pools of MCF7 and MDA-MB-231 cells with LKB1 deple-
tion. We analyzed pLKO.1 and LKB1shRNA stable MCF7
and MDA-MB-231 cell pools for LKB1 protein expression
with immunoblot analysis and found that LKB1 protein
expression was significantly reduced in LKB1shRNA cells
(shRNA1 and shRNA2) as compared with pLKO.1 control
cells (Figure 5d). pLKO.1 and LKB1shRNA cells were trea-
ted with honokiol, and phosphorylation of AMPK was
determined by using Western blot analysis. We found that
honokiol increased phosphorylation of AMPK in pLKO.1
cells. Intriguingly, displaying a crucial role of LKB1, hono-
kiol treatment did not change the phosphorylation levels
of AMPK in LKB1shRNA cells (Figure 5e). Invasion and
migration are the key biologic features of malignant beha-
vior of carcinoma cells [29]. In addition to examining the
effect of LKB1 depletion on honokiol-induced modulation
of AMPK, we also examined the requirement of LKB1 in
honokiol-mediated inhibition of metastatic properties of
breast cancer cells. As evident from Figure 5f, honokiol
treatment efficiently inhibited migration of pLKO.1 cells,
whereas untreated pLKO.1 cells showed increased migra-
tion. Our results showed that LKB1shRNA cells exhibited
increased migration in the absence of honokiol treatment.
Interestingly, honokiol treatment did not inhibit the
migration of LKB1shRNA cells (Figure 5f). We next exam-
ined the effect of honokiol on invasion potential of
pLKO.1 and LKB1shRNA cells and found that honokiol
inhibited invasion of pLKO.1 cells, whereas LKB1shRNA
cells were not affected by honokiol treatment (Figure 5g).
These results collectively show that honokiol-induced
LKB1 overexpression is indeed a crucial component of the
signaling machinery used by honokiol in modulating the
AMPK-S6K axis and inhibiting the metastatic properties
of breast cancer cells.
Honokiol treatment inhibits breast-tumor progression in
athymic nude mice
We investigated the physiological relevance of our in
vitro findings by evaluating whether honokiol has any
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Figure 5 Honokiol increases LKB1 expression, LKB1:STRAD interaction, cytosolic translocation, and depletion of LKB1 abrogates
honokiol-mediated modulation of AMPK, inhibition of migration, and invasion of breast cancer cells. (a) MCF7 and MDA-MB-231 cells
were treated with 2.5 μM honokiol for indicated time intervals. U, untreated cell. Total protein was isolated, and equal amounts of proteins were
resolved with SDS-PAGE and subjected to immunoblot analysis by using specific antibodies for LKB1. The membranes were reblotted by using
actin antibody as control. The blots are representative of multiple independent experiments. The histogram is the mean of densitometric analysis
showing relative density units (RDUs) of the Western blot signals for LKB1 normalized to actin in three independent experiments. *P < 0.005,
compared with untreated controls. (b) MCF7 cells were treated with 2.5 μM honokiol or untreated and subjected to immunoprecipitation assay
by using IgG or LKB1 antibodies, as indicated. Immunoprecipitates were analyzed by using anti-STRAD antibodies. The histogram is the mean of
densitometric analysis showing relative density units (RDUs) of the Western blot signals for STRAD in three independent experiments. *P < 0.005,
compared with untreated controls. (c) MCF7 and MDA-MB-231 cells were treated with honokiol (HNK), and LKB1 protein was analyzed with
immunofluorescence by using LKB1 antibody; 4’6-diamidino-2-phenylindole staining was used to determine the nuclear localization. These results
are representative of multiple independent experiments. (d) LKB1 was depleted in MCF7 and MDA-MB-231 cells by using two different lentiviral
LKB1 short-hairpin RNA (shRNA1 and shRNA2) constructs and a negative control construct that was created in the same vector system (pLKO.1).
Stable pools of LKB1-depleted (LKB1shRNA) and vector control (pLKO.1) cells were used for total protein isolation, and equal amounts of proteins
were subjected to immunoblot analysis by using specific antibodies for LKB1. Actin was used as control. (e) MDA-MB-231-LKB1shRNA (LKB1-sh1
and LKB1-sh2) and MDA-MB-231-pLKO.1 (pLKO.1) cells were treated with honokiol (HNK, 2.5 μM), and phosphorylation of AMPK was analyzed
with Western blot analysis. Total AMPK antibody was used as control. (f) MDA-MB-231-LKB1shRNA (LKB1-sh1 and LKB1-sh2) and MDA-MB-231-
pLKO.1 (pLKO.1) cells were grown to confluence, scratched with a pipette tip, and photographed immediately after scratching (0 hours). Culture
media were replaced with media containing honokiol (HNK, 2.5 μM) or untreated media (U). The plates were photographed at the identical
location of the initial image (0 hours) at 24 hours. The results shown are representative of three independent experiments performed in
triplicate. (g) MDA-MB-231-LKB1shRNA (LKB1-sh1 and LKB1-sh2) and MDA-MB-231-pLKO.1 (pLKO.1) cells were cultured in Matrigel invasion
chambers followed by treatment with honokiol (HNK, 2.5 μM) for 24 hours. The number of cells that invaded through the Matrigel was counted
in five different regions. The slides were blinded to remove counting bias. The result shows the mean of three independent experiments
performed in triplicate. *P < 0.005, compared with untreated controls.
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suppressive effects on the development of breast carci-
noma in nude mouse models and the involvement of
the LKB1-AMPK axis. In the experimental group treated
with honokiol, the rate of tumor growth was signifi-
cantly inhibited, and the tumor size and weight were
significantly reduced compared with control group
(Figure 6a, b). The immunohistochemical assessment of
tumor proliferation showed higher Ki-67 in the control
group as compared with the honokiol-treated group
(Figure 6c). In our in vitro analyses, we discovered the
involvement and requirement of the LKB1-AMPK axis
in biologic functions of honokiol. We examined the
expression of LKB1 and p-AMPK in tumors treated
with honokiol. Tumors treated with honokiol displayed
higher levels of phosphorylated AMPK and LKB1 (Fig-
ure 6c). In addition, we examined the expression levels
of phosphorylated and unphosphorylated AMPK, ACC
as well as S6K, in honokiol-treated and vehicle-treated
mice. We found higher levels of phosphorylated AMPK
and ACC in honokiol-treated tumors as compared with
vehicle-treated controls. Honokiol-treated tumors
showed lower levels of phosphorylated S6K, whereas
vehicle-treated controls exhibited high levels of phos-
phorylated S6K (Figure 6d). These data presented direct
in vivo evidence of the involvement of LKB1-AMPK
activation and the subsequent inhibition of pS6K in
honokiol function (Figure 6e).
Discussion
The antitumor activity of honokiol, a natural product
derived from magnolia plant and used in traditional
Asian medicine, has been reported in various preclinical
models [3]. In the current study, we investigated the
potential of honokiol in the inhibition of migration and
invasion of breast cancer cells and the underlying mole-
cular mechanisms. The following novel findings are
reported in this study: (i) honokiol treatment inhibits
malignant properties such as invasion and migration of
breast cancer cells; (ii) honokiol stimulates AMPK phos-
phorylation and activity while reducing mTOR activity,
as evidenced by reduced phosphorylation of pS6K and
4EBP1; (iii) AMPK protein is required for honokiol-
mediated inhibition of pS6K and 4EBP1; (iv) honokiol
increases the expression and cytosolic localization of
tumor suppressor LKB1, which is an essential effector
molecule to mediate the honokiol effect on the AMPK-
pS6K axis and inhibition of invasion and migration of
breast cancer cells; and (v) honokiol inhibits breast
tumor growth and modulates the LKB1-AMPK-pS6K
axis in vivo. Our results show that honokiol treatment
significantly inhibits malignant properties of breast can-
cer cells through modulation of the LKB1-AMPK-pS6K
axis; thus using honokiol may be a suitable therapeutic
strategy for metastatic breast cancer.
Many bioactive molecules and their synthetic analo-
gues have been reported to demonstrate activity against
breast cancer [68-71]. Although the lower toxicity asso-
ciated with bioactive molecules is a much desired qual-
ity, their limited bioavailability hinders further
development. Honokiol exhibits a desirable spectrum of
bioavailability, in contrast with many other natural pro-
ducts [3]. The development of other polyphenolic agents
has been obstructed by poor absorption and rapid excre-
tion [72]. Honokiol does not have this disability, as sig-
nificant systemic levels of honokiol can be obtained in
preclinical models, and it can cross the blood-brain bar-
rier [73]. These qualities of honokiol make it a promis-
ing small-molecular-weight natural anticancer agent.
Indeed, honokiol has been found to alter many molecu-
lar targets in various cancer models to inhibit tumor cell
growth and survival [3,6,9,10,12,19]. One of the major
findings of this study is that the LKB1-AMPK pathway
plays a major role in mediating the effect of honokiol
effect on migration and invasion of breast cancer cells.
AMPK, a master sensor of cellular energy balance in
mammalian cells, regulates glucose and lipid metabolism
[34]. Biochemical regulation of serine/threonine protein
kinase AMPK activation occurs through multiple mechan-
isms [37]. AMPK undergoes a conformational change in
response to direct binding of AMP to its nucleotide-bind-
ing domain, exposing the activation loop of the catalytic
kinase subunit. LKB1 phosphorylates a critical threonine
in this activation loop to activate AMPK. Dephosphoryla-
tion by protein phosphatases also plays an important role
in regulating AMPK activity [47]. Genetic depletion of
LKB1 in mouse embryonic fibroblasts (MEFs) results in a
loss of AMPK activation after energy stresses that increase
AMP [37], showing the requirement of LKB1 in AMPK
activation. We found that honokiol increases AMPK acti-
vation, which can be efficiently inhibited by the silencing
of LKB1. AMPK represents a pivotal point in the mTOR
pathway regulating a vast range of cellular activities,
including transcription, translation, cell size, mRNA turn-
over, protein stability, ribosomal biogenesis, and cytoskele-
tal organization [37]. Besides being directly activated by
tumor-suppressor LKB1, AMPK itself regulates the activa-
tion of two other tumor suppressors, TSC1 and TSC2,
which are critical regulators of Rheb and mTOR [37]. We
found that AMPK knockdown inhibits honokiol-mediated
mTOR inhibition. Honokiol-mediated inhibition of mTOR
also suggests that honokiol and its derivatives may prove
excellent candidates as targeted therapies for carcinomas
characterized by hyperactive mTOR signaling.
LKB1 kinase is a tumor suppressor and a key determi-
nant in the Peutz-Jeghers syndrome, an inherited sus-
ceptibility to gastrointestinal, lung, pancreatic, and
breast cancer [47,74]. Inactivation of the LKB1 gene has
been shown in a subset of sporadic lung and pancreatic
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Figure 6 Honokiol treatment inhibited breast tumor growth in nude mice. MDA-MB-231 cells-derived tumors were developed in nude
mice and treated with vehicle or honokiol (HNK). (a) Tumor growth was monitored by measuring the tumor volume for 4 weeks (eight mice
per group). (b) At the end of 6 weeks, tumors were collected, measured, weighed, and photographed. Honokiol treatment inhibited tumor size
as compare with vehicle treatment. Average tumor weight and representative tumor images are shown here. (c) Tumor samples were subjected
to immunohistochemical analysis by using LKB1, p-AMPK, and Ki67 antibodies. Honokiol (HNK) treatment decreased the expression of Ki-67,
increased expression of LKB1 and pAMPK, as compared with vehicle treatment. Bar diagrams show quantitation of protein expression in tumors
from vehicle- and honokiol-treated mice. Columns, mean (n = 8); bar, SD. *Significantly different (P < 0.005) compared with control. (d) Tumor
lysates (from two different tumors from each set) were subjected to immunoblot analysis by using phospho-AMPK (p-AMPK), AMPK, phospho-
ACC (p-ACC), ACC, phospho-pS6K, pS6K antibodies. Actin antibody was used as control. (e) A model of honokiol (HNK)-stimulated AMPK
activation in breast cancer cells. Honokiol stimulation induces LKB1 translocation from the nucleus into cytosol and phosphorylates AMPK,
leading to increased phosphorylation of ACC and decreased phosphorylation of pS6K and 4EBP1.
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cancer. Although the loss of LKB1 expression is not
commonly observed in human breast carcinoma, it cer-
tainly correlates with high-grade DCIS and high-grade
invasive ductal carcinoma [61]. It is important to note
that LKB1 expression was not abrogated in pure DCIS
cases but only in the DCIS associated with invasion,
indicating that loss of LKB1 could potentially promote
invasion. Supporting this notion, low LKB1 protein
levels have been reported to correlate with poor prog-
nosis in breast carcinoma [48]. Our studies show that
honokiol treatment increases the expression and cytoso-
lic localization of LKB1 in breast xenograft tumors and
inhibits tumor growth. LKB1 is localized predominantly
in the nucleus, translocating to the cytosol, either by
forming a heterotrimeric complex with STRAD (ste20-
related adaptor protein) and MO25 (mouse protein 25)
or by associating with LIP1 (LKB1-interacting protein),
to exert its biologic functions [50,52,55,75,76]. The cyto-
plasmic pool of LKB1 plays an important role in mediat-
ing its tumor-suppressor properties. Wild-type LKB1,
when co-expressed with STRAD and MO25, exhibits
increased cytoplasmic localization, whereas mutant
LKB1, unable to interact with STRAD and MO25,
remains in the nucleus [75,77]. Promotion of cytosolic
translocation of LKB1 is a common mechanism to acti-
vate downstream LKB1 functions, as AMPK activation
by metformin, peroxynitrile, or adiponectin also involves
LKB1 cytosolic translocation [22,64,78-80]. Honokiol
treatment increases LKB1-STRAD complex formation in
addition to overexpression of LKB1, thus increasing the
functional pool of LKB1. Our study shows for the first
time that honokiol stimulates the cytosolic translocation
of LKB1 in breast cancer cells.
Conclusions
We uncovered a novel mechanism by which honokiol
inhibits invasion and migration of breast cancer cells,
which involves enhanced expression and cytosolic locali-
zation of LKB1 and AMPK activation. We also demon-
strated the requirement of LKB1 and AMPK in
honokiol-mediated inhibition of migration and invasion
of breast cancer cells. Our results thus provide new
insight into the mechanisms by which honokiol, a pro-
mising anticancer agent, inhibits breast carcinogenesis.
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Additional material
Additional file 1: Honokiol inhibits clonogenicity and anchorage-
independent growth of HCC-1806 breast cancer cells. (a) HCC-1806
breast cancer cells were treated with various concentrations of honokiol
(HNK) (as indicated) and subjected to clonogenicity assay. U, untreated
cells. Colonies containing > 50 normal-appearing cells were counted. *P
< 0.005, compared with untreated controls. (b) HCC-1806 breast cancer
cells were subjected to soft-agar colony-formation assay in the presence
of various concentrations of honokiol for 3 weeks. U, untreated cells.
Results are expressed as average number of colonies counted (in six
microfields). *P < 0.001, compared with untreated controls.
Additional file 2: Honokiol inhibits migration and invasion of breast
cancer cells. Confluent layer of MCF7 and MDA-MB-231 breast cancer
cells grown on electric cell-substrate impedance sensing (ECIS) 8W1E
plates was subjected to an elevated voltage pulse of 40 kHz frequency,
3.5 V amplitude for 30 seconds to create a wound, and resistance was
measured for 24 hours in the presence (HNK, 2.5 μM) and absence (U) of
honokiol to monitor the migration of breast cancer cells. Honokiol
treatment inhibited migration of breast cancer cells in an ECIS assay. All
the experiments were performed thrice in triplicate.
Additional file 3: Honokiol does not modulate Akt activation in
breast cancer cells. MCF7 and MDA-MB-231 cells were treated with
honokiol (HNK, 2.5 μM) for indicated time intervals. U, untreated cells.
Total protein was isolated, and equal amounts of proteins were resolved
with SDS-PAGE and subjected to immunoblot analysis by using specific
antibodies for phosphorylated Akt. The membranes were reblotted by
using total Akt antibodies as controls. The blots are representative of
multiple independent experiments.
Additional file 4: AMPK knockdown abrogates honokiol-mediated
inhibition of migration. Confluent layer of WT and AMPK-null MEFs
grown on electric cell-substrate impedance sensing (ECIS) 8W1E plates
was subjected to an elevated voltage pulse of 40 kHz frequency, 3.5 V
amplitude, for 30 seconds to create a wound, and resistance was
measured for 24 hours in the presence (HNK, 2.5 μM) and absence (U) of
honokiol to monitor the migration of MEFs. All the experiments were
performed thrice in triplicate.
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